Joseph Walewicz

Joseph Walewicz has a long and varied work experience. Joseph began their career in 2004 as Vice President, Senior Health Care Analyst at Orion Securities (now Macquarie Capital Markets). In 2005, they joined CIBC World Markets as Executive Director, Equity Research. In 2009, they became Vice President at Paladin Labs, and Chief Operating Officer at Paladin Biosciences (a division of Paladin Labs). In 2011, they joined MethylGene Inc. as Vice President, Business and Corporate Development, and also became a Board Member at Warnex. In 2014, they moved to Laurentian Bank Securities as Vice President, Healthcare, Institutional Equity Research. In 2017, they joined Clementia Pharmaceuticals Inc. as Executive Vice President, Business and Corporate Development. In 2021, they became Chief Financial Officer at Fibrocor Therapeutics, and also holds the roles of Chief Executive Officer and Chief Business Officer at NeuPath Health (TSXV:NPTH).

Joseph Walewicz obtained their MBA in Finance from McGill University between 1993 and 1996. Prior to that, they obtained a B.Sc. in Biochemistry and a B.A. in Economics from Queen's University between 1988 and 1993. In 2013, they obtained a Certified Licensing Professional (CLP) from Certified Licensing Professionals, Inc. Joseph also holds a Chartered Financial Analyst (CFA) from the CFA Institute.